Spero Therapeutics, Inc. Logo

Spero Therapeutics, Inc.

Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.

SPRO | US

Overview

Corporate Details

ISIN(s):
US84833T1034
LEI:
Country:
United States of America
Address:
675 MASSACHUSETTS AVENUE, 2139 CAMBRIDGE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company aims to address the growing threat of antibiotic resistance by advancing a pipeline of innovative medicines. A key candidate, tebipenem HBr, is an oral antibiotic developed for complicated urinary tract infections that has successfully completed Phase 3 trials. Spero Therapeutics actively pursues strategic partnerships to maximize the global reach and impact of its therapies for patients in need.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Spero Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Spero Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Spero Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
BRISTOL MYERS SQUIBB CO Logo
Develops innovative medicines for oncology, immunology, and cardiovascular diseases.
United States of America BMY
R&D pharma firm developing drugs for CNS disorders, oncology, and metabolic diseases.
South Korea 003000
Burning Rock Biotech Ltd Logo
Offers NGS-based diagnostics for precision oncology, from detection to clinical trial support.
United States of America BNR
C4 Therapeutics, Inc. Logo
Developing protein degrader medicines to treat cancer and other serious diseases.
United States of America CCCC
Cabaletta Bio, Inc. Logo
Develops engineered T cell therapies for a curative reset in autoimmune diseases.
United States of America CABA
Cadrenal Therapeutics, Inc. Logo
Developing novel anticoagulant therapies for high-risk cardiovascular patients.
United States of America CVKD
CalciMedica, Inc. Logo
Develops CRAC channel inhibitors for critical illnesses like acute pancreatitis & AKI.
United States of America CALC
Calidi Biotherapeutics, Inc. Logo
Develops immunotherapies using stem cells to deliver oncolytic viruses against solid tumors.
United States of America CLDI
Calliditas Therapeutics Logo
Develops and commercializes novel treatments for rare renal and hepatic diseases like IgA nephropathy.
Sweden CALTX
CALTH. Inc Logo
Develops AI-powered rapid diagnostic solutions for point-of-care and self-testing.
South Korea 402420

Talk to a Data Expert

Have a question? We'll get back to you promptly.